Skip to main content
SYRE
NASDAQ Life Sciences

Spyre's SPY003 Hits Primary Endpoint in UC, Completing POC for All Three IBD Components

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$88.4
Mkt Cap
$7.846B
52W Low
$14.505
52W High
$110.175
52W Position info
509% above low
Off High info
20% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $14.505.

Summary

Spyre reported positive Phase 2 SKYLINE Part A induction data for SPY003 (anti-IL-23) in ulcerative colitis. The drug met its primary endpoint with a statistically significant 10.0-point reduction in RHI score (p<0.0001), along with 20% clinical remission and 30% endoscopic improvement. Safety was consistent with the IL-23 class, with no drug-related serious adverse events. This completes proof-of-concept for all three components of Spyre's IBD combination strategy, following earlier positive data for SPY001 and SPY002. The company is now enrolling Part B of SKYLINE, which will test pairwise combinations, with topline data expected in 2027. This milestone strengthens the rationale for the combination approach and positions Spyre as a leader in next-generation IBD therapies.

At the time of this announcement, SYRE was trading at $88.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $14.51 to $110.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $96.60 info
Change: -$3.13 (-3%) info
Market Cap: $9.173B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $96.60 info
Change: -$3.13 (-3%) info
Market Cap: $9.173B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $96.60 info
Change: +$16.09 (+20%) info
Market Cap: $9.173B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $96.60 info
Change: +$16.49 (+21%) info
Market Cap: $9.173B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $96.60 info
Change: +$15.44 (+19%) info
Market Cap: $9.173B info